Blog
Blog
The CI Capacity Squeeze, and Three Questions To Ask Before 2027 Planning
Every year the competitive field gets more crowded: more assets, more readouts, more congress abstracts, more competitor moves to track. Products are more complex too, from special distribution to patient and healthcare professional (HCP) education requirements. And every year, pharma competitive intelligence (CI) teams are asked to cover more of it. What’s changed is that resources aren’t keeping up.
Filter posts by:
Blog
Assessing the Value of Non-Curative Cell and Gene Therapies
Executive Summary Trinity’s Take: Manufacturers should prioritize refining and tailoring their value messaging to communicate the incremental value that their therapy provides over current treatments, optimize their pricing strategy based on the cost-offsets their product generates, and pursue contracting strategies to...
Blog
The 2021 German Federal Election: What is the Future Outlook for Healthcare in Germany?
Written by Caspar Kengeter and Manon Ricard
Blog
AI-Based Software Paige Prostate is Granted FDA Approval Through the De Novo Regulatory Pathway
Paige Prostate is the first artificial intelligence (AI)-based software designed to identify areas of concern (i.e., high likelihood of containing cancer) on a prostate biopsy image so they can be flagged for further review by a pathologist. The program is...
Blog
Part II: Non-Traditional Players Attempting Entry into the Healthcare Sector
Executive Summary Trinity’s Take: Walmart’s partnership with Novo Nordisk promises key benefits to diabetes patients (e.g., cost savings, improved access), but the extent of the benefit remains to be seen. Instead, the partnership is likely to prompt a response by...
Blog
Part I: Non-Traditional Players Attempting Entry Into the Healthcare Sector
Executive Summary Trinity’s take: Non-traditional players that have been successful in tapping into the healthcare sector seem to follow a strategy of patience, acquirement of ample infrastructure and expertise, sufficient capital, and beneficial partnerships and acquisitions. On the other hand, the...
Blog
Exploring the Impact of COVID-Driven Trends on the US Healthcare Landscape
Executive Summary Trinity’s Take: A review of changes since March 2020 to patients / providers, payers, clinical research, and pharmaceutical distribution within the US reveals that there is increased use and coverage of telemedicine, interest in more targeted clinical research,...
